The waiver of the Nasdaq listing condition and $25M equity credit line suggests the merged entity may close without a public listing or committed capital, increasing post-merger funding risk. The pledge of all Altanine IP to an affiliate creditor creates a senior claim on the combined company's core assets. Monitor for the remaining closing conditions and any subsequent financing or listing announcements.
Price Chart
Executive Summary
Polomar Health Services and Altanine waived five key closing conditions for their merger, including the S-4 effectiveness, Nasdaq listing approval, a $25M equity credit line, a reverse stock split to $10/share, and concurrent financing. The company also consented to Altanine granting a security interest in all assets of its subsidiary Pinata Holdings (including all patents) to an affiliate, CWR 1. Separately, CEO Terrence Tierney agreed to resign as CEO/President upon closing and become EVP/COO, with his salary retroactively reduced to $19,000/month and bonus converted to discretionary. The waivers remove major hurdles but also signal the deal is proceeding without key protections, and the asset pledge creates creditor priority over Altanine's IP.
Key Financial Metrics
Key Facts
- Five merger conditions waived: S-4 effectiveness, Nasdaq listing, $25M equity credit line, reverse split to $10/share, and concurrent financing
- Polomar consented to Altanine granting a security interest in all assets of Pinata Holdings (including all patents) to affiliate CWR 1
- CEO Tierney to resign as CEO/President upon merger close and become EVP/COO
- Tierney's base salary retroactively reduced to $19,000/month from $24,000; bonus changed from 75% target to discretionary
- Tierney granted additional 500,000 nonqualified stock options; 100,000 shares fully vested
- Accrued base salary of $72,961.51 to be paid in $2,500 installments starting July 1, 2026
- Merger agreement originally dated July 23, 2025, amended October 8, 2025
Financial Impact
No deal value disclosed. CEO salary reduced by ~$5,000/month. $72,961.51 in accrued salary to be paid out. 500,000 new options granted to CEO.
Risk Factors
- Merger closing without Nasdaq listing or committed $25M equity line leaves post-merger entity without public market access or committed capital
- Security interest granted to CWR 1 over all Altanine IP (including patents) creates creditor priority that could impair the combined company's asset base
- CEO transition and reduced compensation may signal management instability or cost-cutting pressure
- No financial terms of the merger disclosed; valuation and dilution unknown
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023937 |
| Exhibit: ex10-2.htm | 0001493152-26-023937 |
| Exhibit: ex10-1.htm | 0001493152-26-023937 |
| Document: 0001493152-26-023937-index-headers.html | 0001493152-26-023937 |
| Document: 0001493152-26-023937-index.html | 0001493152-26-023937 |
| Document: 0001493152-26-023937.txt | 0001493152-26-023937 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.1236 | awaiting T+60 | — | $0.1500 (+21.36%) |
Sep 24, 2026 4w ago | EFFECT | $0.1500 | awaiting T+60 | — | $0.1500 (+0.00%) |
May 15, 2026 23w ago | 8-K | $0.3000 $0.1500 | ▼ −50.00% | ▼ −54.85% | $0.1500 (−50.00%) |
Apr 29, 2026 25w ago | 8-K | $0.1200 $0.0800 | ▲ +33.33% | ▲ +36.44% | $0.1500 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers